RenovoRx RNXT highlights peer-reviewed PK/PD data for TAMP targeting
RenovoRx (RNXT) highlights a peer-reviewed publication presenting pharmacokinetic and pharmacodynamic (PK/PD) data supporting its TAMP™ targeted drug-delivery platform in locally advanced pancreatic cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.